Factor XIII B Inhibitors
Factor XIII B inhibitors are a class of chemicals that specifically target and inhibit the function of the Factor XIII B subunit. Factor XIII is a pro-enzyme in the coagulation cascade, primarily responsible for stabilizing blood clots by cross-linking fibrin molecules. This enzyme is a heterotetramer composed of two A subunits and two B subunits, each playing distinct roles in its activation and function. The B subunit, while not directly involved in the catalytic activity, acts as a carrier for the A subunit in the plasma, maintaining its solubility and regulating its availability. Inhibitors targeting the B subunit work by interfering with this regulatory process, which can alter the overall activity and stability of Factor XIII in the blood.
The Factor XIII protein itself undergoes activation via thrombin and calcium, where the A subunit becomes enzymatically active and cross-links fibrin to strengthen the blood clot. The B subunit does not participate directly in these reactions but is crucial for transporting and stabilizing the A subunit before activation. Inhibition of the B subunit can lead to disruption in the localization or activation of Factor XIII, potentially impacting the efficiency of fibrin stabilization. This mechanism highlights the importance of the B subunit as more than just a passive player, acting instead as a key regulatory component in the coagulation pathway. By controlling the interaction between A and B subunits, these inhibitors provide insight into the intricate balance required for proper blood clot formation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A may downregulate Factor XIII B expression by altering acetylation patterns of histones associated with the gene's promoter region, leading to a tighter chromatin structure and decreased accessibility for transcription machinery. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This compound could decrease Factor XIII B gene expression by inducing hypomethylation of DNA. Hypomethylated DNA at the Factor XIII B locus may recruit repressive histone modifications, leading to silenced gene expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A might bind selectively to the G-C rich regions of the Factor XIII B gene promoter, competitively inhibiting the binding of specific transcription factors required for the gene's expression, thereby reducing its transcriptional initiation. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
By intercalating between guanine-cytosine base pairs of DNA, Actinomycin D could inhibit the progression of RNA polymerase along the Factor XIII B gene, leading to a decrease in mRNA transcription and subsequent protein synthesis. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin (Sirolimus) might indirectly decrease Factor XIII B protein synthesis by inhibiting the mTOR pathway, which is involved in the initiation of protein translation. This inhibition could reduce the overall translation rate, including that of Factor XIII B subunits. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine may reduce Factor XIII B mRNA transcription by intercalating into DNA and RNA. This intercalation might obstruct the transcriptional machinery, leading to a general downregulation of mRNA synthesis, including that of Factor XIII B. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Inhibiting topoisomerase I with Camptothecin could trigger DNA damage responses and cell cycle arrest, which may include the downregulation of certain clotting factors like Factor XIII B as a part of the cell's efforts to mitigate DNA replication stress. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
By inhibiting DNA topoisomerase II, Etoposide could induce double-strand DNA breaks, leading to cell cycle checkpoints activation and possibly a targeted decrease in the transcription of genes involved in cell proliferation and repair, including the Factor XIII B gene. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB could directly inhibit RNA polymerase II activity, resulting in a decrease in the elongation phase of mRNA synthesis. This could lead to a reduction in the transcription levels of Factor XIII B, among other genes. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin may inhibit RNA polymerase II with high specificity, leading to a potent decrease in mRNA production, including the transcripts of the Factor XIII B gene, thereby reducing its expression at the post-transcriptional level. | ||||||